Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Pembrolizumab in Patients with Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL): Data from the Keynote-013 and Keynote-170 Studies

Blood (2018) 132 (Supplement 1): 228.

https://doi.org/10.1182/blood-2018-99-110220

Published: 2018

Journal Articles

Two-Year Follow-up of Keynote-087 Study: Pembrolizumab Monotherapy in Relapsed/Refractory Classic Hodgkin Lymphoma

Pier Luigi Zinzani, MD, Robert W. Chen, MD, Hun Ju Lee, MD, Philippe Armand, MD PhD, Nathalie A Johnson, MD PhD, Pauline Brice, MD, John Radford, MD FRCP, Vincent Ribrag, MD, Daniel Molin, Theodoros P. Vassilakopoulos, MD PhD, Akihiro Tomita, MD PhD, Bastian Von Tresckow, MD, Margaret A. Shipp, MD, Eunhee Kim, Akash Nahar, MD MPH, Arun Balakumaran, MD PhD SM, Craig H. Moskowitz, MD

Blood (2018) 132 (Supplement 1): 2900.

https://doi.org/10.1182/blood-2018-99-117045

Published: 2018

Journal Articles

Pembrolizumab Antitumor Activity in Relapsed/Refractory Classical Hodgkin Lymphoma in Keynote-087: Revised Response Criteria for Malignant Lymphoma 2007 Criteria Versus Lugano 2014 Classification

Craig H. Moskowitz, MD, Robert W. Chen, MD, Philippe Armand, MD PhD, Pier Luigi Zinzani, MD, Theodoros P. Vassilakopoulos, MD PhD, Gregory V. Goldmacher, MD PhD MBA, Jianxin Lin, MS, Akash Nahar, MD MPH, Arun Balakumaran, MD PhD SM, Gilles Salles, MD PhD

Blood (2017) 130 (Supplement 1): 4085.

https://doi.org/10.1182/blood.V130.Suppl_1.4085.4085

Published: 2017

Journal Articles

Pembrolizumab in Relapsed/Refractory Classical Hodgkin Lymphoma: Primary End Point Analysis of the Phase 2 Keynote-087 Study

Craig H. Moskowitz, MD, Pier Luigi Zinzani, MD PhD, Michelle A. Fanale, MD, Philippe Armand, MD PhD, Nathalie A. Johnson, John A. Radford, MD, Vincent Ribrag, MD, Daniel Molin, MD PhD, Theodoros P. Vassilakopoulos, MD PhD, Akihiro Tomita, MD PhD, Bastian von Tresckow, MD, Margaret A. Shipp, MD, Eric Gustafson, PhD, Yinghua Zhang, PhD, Alejandro Daniel Ricart, MD, Arun Balakumaran, MD PhD SM, Robert W Chen, MD

Blood (2016) 128 (22): 1107.

https://doi.org/10.1182/blood.V128.22.1107.1107

Published: 2016

Journal Articles

Pembrolizumab in Patients with Classical Hodgkin Lymphoma after Brentuximab Vedotin Failure: Long-Term Efficacy from the Phase 1b Keynote-013 Study

Philippe Armand, MD PhD, Margaret A. Shipp, MD, Vincent Ribrag, MD, Jean-Marie Michot, MD, Pier Luigi Zinzani, MD PhD, John Kuruvilla, MD, Ying Zhu, PhD, Alejandro Daniel Ricart, MD, Arun Balakumaran, MD PhD SM, Craig H. Moskowitz, MD

Blood (2016) 128 (22): 1108.

https://doi.org/10.1182/blood.V128.22.1108.1108

Published: 2016

Journal Articles

Pembrolizumab, a PD-1 Inhibitor, in Patients with Myelodysplastic Syndrome (MDS) after Failure of Hypomethylating Agent Treatment

Guillermo Garcia-Manero, MD, Martin S. Tallman, MD, Giovanni Martinelli, MD, Vincent Ribrag, MD, Hui Yang, MD PhD, Arun Balakumaran, MD PhD SM, Sabine Chlosta, MD, Yayan Zhang, PhD, B. Douglas Smith, MD

Blood (2016) 128 (22): 345.

https://doi.org/10.1182/blood.V128.22.345.345

Published: 2016

Journal Articles

Phase 1b Study of Pembrolizumab in Patients with Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Results from the Ongoing Keynote-013 Trial

Pier Luigi Zinzani, MD PhD, Vincent Ribrag, MD, Craig H. Moskowitz, MD, Jean-Marie Michot, MD, John Kuruvilla, MD, Arun Balakumaran, MD PhD SM, Yayan Zhang, PhD, Patricia Marinello, PharmD, Sabine Chlosta, MD, Eric Gustafson, PhD, Margaret A. Shipp, MD, Philippe Armand, MD PhD

Blood (2016) 128 (22): 619.

https://doi.org/10.1182/blood.V128.22.619.619

Published: 2016

Journal Articles

Utilization Patterns and Resource Use in Relapse/Refractory Hodgkin Lymphoma (rrHL) Patients Treated with Brentuximab Vedotin (BV)

Changxia Shao, PhD, Jinan Liu, PhD, Wei Zhou, PhD, Monika Kumar Raut, PhD, Matthew Monberg, PhD, Xiting Cao, PhD, Alejandro Daniel Ricart, MD, Arun Balakumaran, MD PhD SM

Blood (2016) 128 (22): 2377.

https://doi.org/10.1182/blood.V128.22.2377.2377

Published: 2016

Journal Articles

PD-1 Blockade with Pembrolizumab in Patients with Classical Hodgkin Lymphoma after Brentuximab Vedotin Failure: Safety, Efficacy, and Biomarker Assessment

Philippe Armand, MD PhD, Margaret A. Shipp, MD, Vincent Ribrag, MD, Jean-Marie Michot, Pier Luigi Zinzani, MD PhD, Martin Gutierrez, MD, Ellen Snyder, PhD, Alejandro D. Ricart, MD, Arun Balakumaran, MD PhD SM, Craig H. Moskowitz, MD

Blood (2015) 126 (23): 584.

https://doi.org/10.1182/blood.V126.23.584.584

Published: 2015

Journal Articles

Pembrolizumab in Combination with Lenalidomide and Low-Dose Dexamethasone for Relapsed/Refractory Multiple Myeloma (RRMM): Keynote-023

Jesus San Miguel, MD PhD, Maria-Victoria Mateos, MD PhD, Jatin J. Shah, MD, Enrique M. Ocio, MD PhD, Paula Rodriguez-Otero, MD PhD, Donna Reece, MD, Nikhil C. Munshi, MD, David Avigan, MD, Yang Ge, PhD, Arun Balakumaran, MD PhD SM, Patricia Marinello, PharmD, Robert Z. Orlowski, MD PhD, David Siegel, MD PhD

Blood (2015) 126 (23): 505.

https://doi.org/10.1182/blood.V126.23.505.505

Published: 2015

Journal Articles

Phase 1b Study of PD-1 Blockade with Pembrolizumab in Patients with Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL)

Pier Luigi Zinzani, MD PhD, Vincent Ribrag, MD, Craig H. Moskowitz, MD, Jean-Marie Michot, John Kuruvilla, MD, Arun Balakumaran, MD PhD SM, Ellen Snyder, PhD, Patricia Marinello, PharmD, Margaret A. Shipp, MD, Philippe Armand, MD PhD

Blood (2015) 126 (23): 3986.

https://doi.org/10.1182/blood.V126.23.3986.3986

Published: 2015

NARROW

Pembrolizumab in Patients with Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL): Data from the Keynote-013 and Keynote-170 Studies

Two-Year Follow-up of Keynote-087 Study: Pembrolizumab Monotherapy in Relapsed/Refractory Classic Hodgkin Lymphoma

Pembrolizumab Antitumor Activity in Relapsed/Refractory Classical Hodgkin Lymphoma in Keynote-087: Revised Response Criteria for Malignant Lymphoma 2007 Criteria Versus Lugano 2014 Classification

Pembrolizumab in Relapsed/Refractory Classical Hodgkin Lymphoma: Primary End Point Analysis of the Phase 2 Keynote-087 Study

Pembrolizumab in Patients with Classical Hodgkin Lymphoma after Brentuximab Vedotin Failure: Long-Term Efficacy from the Phase 1b Keynote-013 Study

Pembrolizumab, a PD-1 Inhibitor, in Patients with Myelodysplastic Syndrome (MDS) after Failure of Hypomethylating Agent Treatment

Phase 1b Study of Pembrolizumab in Patients with Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Results from the Ongoing Keynote-013 Trial

Utilization Patterns and Resource Use in Relapse/Refractory Hodgkin Lymphoma (rrHL) Patients Treated with Brentuximab Vedotin (BV)

PD-1 Blockade with Pembrolizumab in Patients with Classical Hodgkin Lymphoma after Brentuximab Vedotin Failure: Safety, Efficacy, and Biomarker Assessment

Pembrolizumab in Combination with Lenalidomide and Low-Dose Dexamethasone for Relapsed/Refractory Multiple Myeloma (RRMM): Keynote-023

Phase 1b Study of PD-1 Blockade with Pembrolizumab in Patients with Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only